Outcomes of bortezomib combination chemotherapies in autologous stem cell transplantation-ineligible patients with AL amyloidosis

BACKGROUND: Treatment protocols for light chain (AL) amyloidosis have been derived from myeloma treatment. Bortezomib is a key drug used for the treatment of myeloma and AL amyloidosis. We retrospectively investigated the efficacy and toxicity of bortezomib-based chemotherapy in patients with newly...

Descripción completa

Detalles Bibliográficos
Autores principales: Hur, Joon Young, Yoon, Sang Eun, Kim, Darae, Choi, Jin-oh, Min, Ju-Hong, Kim, Byung Jun, Kim, Jung Sun, Lee, Jung Eun, Choi, Joon Young, Jeon, Eun-Seok, Kim, Seok Jin, Kim, Kihyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721454/
https://www.ncbi.nlm.nih.gov/pubmed/34801989
http://dx.doi.org/10.5045/br.2021.2021121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721454/
https://www.ncbi.nlm.nih.gov/pubmed/34801989
http://dx.doi.org/10.5045/br.2021.2021121

Ejemplares similares